Renal prognoses by different target hemoglobin levels achieved by epoetin beta pegol dosing to chronic kidney disease patients with hyporesponsive anemia to erythropoiesis-stimulating agent: a multicenter open-label randomized controlled study
ConclusionsIn NDD-CKD patients with ESA-hyporesponsive renal anemia, the aggressive administration of ESA did not clearly extend kidney survival or result in a significant difference in the incidence of CV events.
Source: Clinical and Experimental Nephrology - Category: Urology & Nephrology Source Type: research
More News: Anemia | Cardiology | Cardiovascular | Chronic Kidney Disease | Dialysis | Heart | Kidney Transplant | Kidney Transplantation | Study | Transplants | Urology & Nephrology